PURPOSE: To examine retrospectively fractionated high-dose-rate brachytherapy as monotherapy for @entity263 with special focus on tolerance and @entity137 , especially chronic @entity137 . MATERIALS AND METHODS: Between May 1995 and October 2001, 43 @entity1 with @entity263 were treated with high-dose-rate brachytherapy without external beam irradiation at Osaka University Hospital. The stage was T1, T2, T3, and T4 in 8, 14, 18, and 3 @entity1 , respectively. The @entity420 was well, moderately, or poorly differentiated in 12, 16, and 15 @entity1 , respectively. The median initial @entity1486 level was 19.3 ng/mL (range 3.8-233.0). Thirty-eight @entity1 also received hormonal therapy. Metallic needles were implanted transperineally under real-time ultrasound guidance, followed by a dose optimization program. @entity1 were irradiated twice daily at intervals of >6 h. A total dose of 54 Gy in nine fractions within 5 days (48 Gy in eight fractions within 5 days for the first 7 cases) was administered in one implant session. The median follow-up was 24 months (range 1-76). RESULTS: Radiation Therapy Oncology Group acute @entity137 of Grade 4, 2, and 1 occurred in 1 (2%), 12 (28%), and 8 (19%) @entity1 , respectively. Five @entity1 had late @entity137 : one with rectal ulcer (Grade 2) and four with @entity548 (Grade 1). The volume receiving 100% of the prescribed dose showed significant correlations with the incidence of acute and chronic @entity137 (p = 0.005 and p = 0.014, respectively). The 3-year actuarial overall survival, local control, and biochemical no evidence of disease rate was 94%, 100%, and 55%, respectively. The crude biochemical control rate for low, intermediate, and high-risk @entity1 was 100% (5 of 5), 80% (8 of 10), and 61% (17 of 28), respectively. CONCLUSIONS: High-dose-rate brachytherapy as monotherapy was found to be feasible and well tolerated. It showed a low chronic @entity137 rate without any event of Radiation Therapy Oncology Group of Grade 3 or greater.

High-dose-rate brachytherapy as monotherapy for @entity263 : a retrospective analysis with special focus on tolerance and chronic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer'] @entity548 :: ('MESH:D006470', 'Disease') :: ['rectal bleeding'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
